Program
Please note that this meeting will take place as an in-person event in Toronto and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
Sunday, October 1, 2023
Welcome and Opening Keynote Lecture
Monday, October 2
Plenary Session 1: T-cell Biology
Plenary Session 2: Macrophages and Myeloid Cells
Plenary Session 3: Inhibitory Cells
Tuesday, october 3
Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Plenary Session 5: Metabolic Modulation of Anti-tumor Immunity
Plenary Session 6: TCR-targeted Immunotherapies
Wednesday, octoBer 4
Plenary Session 7: Spatial Profiling
Plenary Session 8: Synthetic Biology and Immune Cell Engineering
Plenary Session 9: Engineered Cytokines
Sunday, October 1, 2023
Registration
3-8 p.m. | Metropolitan Ballroom Foyer
Welcome and oPENInG Keynote Lecture
6:30-7:30 P.M. | Metropolitan Ballroom West
Welcome and Opening Keynote Lecture
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington
Keynote Lecture
Chasing T Cell Exhaustion
Crystal L. Mackall, Stanford University School of Medicine, Stanford, California
Opening reception
7:30-9:30 p.m. | Metroplitan ballroom east
Monday, october 2
Continental breakfast
7-8 a.m. | Metropolitan ballroom centre
Plenary Session 1: T-cell Biology
Session Chair: Andrea Schietinger, Memorial Sloan Kettering Cancer center, New York, New York
8-10:05 A.M. | Metropolitan ballroom West
Critical role for Batf3-lineage dendritic cells within the tumor microenvironment
Thomas F. Gajewski, University of Chicago, Chicago, Illinois
Title to be announced
Andrea Schietinger
Elucidating mechanisms of immunotherapy response and resistance in pancreatic cancer
Ingunn Stromnes, University of Minnesota Medical School, Minneapolis, Minnesota
Regulation of exhausted CD8+ T cell differentiation by IKZF transcription factors*
Sinead M. Reading, Peter MacCallum Cancer Centre, Melbourne, Australia
Panel Discussion
bREAK
10:05-10:25 A.M. | metropolitan ballroom foyer
pLENARY sESSION 2: MACROPHAGES AND MYELOID CELLS
Session Chair: Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, MASSACHUSETTS
10:25 A.M.-12:30 p.m. | Metroplitan Ballroom west
Immune archetypes and the shifting paradigms of myeloid biology in cancer
Matthew Krummel, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Decoding clinically distinct multicellular circuits and myeloid phenotypes in cancer
Aaron M. Newman, Stanford University, Stanford, California
Unraveling the complexities of tumor associated macrophages for anti-cancer therapy of breast cancer
Jennifer L. Guerriero
Lyn kinase regulates myeloid-cell responses to mammary tumors*
Joseph T. Greene, Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota
Panel Discussion
Lunch on Own/Free Time
12:30-2:30 P.M.
Plenary session 3: Inhibitory Cells
session chair: pamela S. Ohashi, uhn princess margaret cancer Centre, toronto, ontario, canada
2:30-4:35 p.m. | METROPOLITAN BALLROOM WEST
Hyperactivated CD4+ T cells lacking FoxP3 inhibit therapeutics tumor immunity
Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri
Inhibitory ILCs, B7-H3, and anti-tumor immunity
Pamela S. Ohashi
PMN-MDSC in regulation of immune suppressive microenvironment in cancer
Dmitry Gabrilovich, AstraZeneca, Philadelphia, Pennsylvania
Hypoxia promotes inflammatory fibroblast formation in pancreatic cancer*
Ashley M. Mello, University of Michigan, Ann Arbor, Michigan
Panel Discussion
pOSTER SESSION A/RECEPTION
4:45-7:00 P.M. | metropolitan ballroom east
Abstracts to be presented at the conference
eVENING OFF/DINNER ON OWN
7:00 P.M.
tUESDAY, OCTOBER 3
Continental Breakfast
7-8 A.M. | metropolitan ballroom centre
Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Session Chair: Dario a. a. vignali, University of pittsburgh, Pittsburgh, pennsylvania
8-10:05 A.M. | metropolitan ballroom west
Interferon modification of T cell function and response to immunotherapy
David G. Brooks, University of Toronto, Toronto, Ontario, Canada
Title to be announced
Tak W. Mak, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
LAG-3: The third checkpoint inhibitor & its synergistic interactions with PD1
Dario A. A. Vignali
Temporal single cell profiling identifies B-cell specific checkpoint molecules that regulate anti-tumor immunity*
Lloyd Bod, Massachusetts General Hospital, Boston, Massachusetts
Panel Discussion
Break
10:05-10:25 A.M. | metropolitan ballroom foyer
Plenary Session 5: Metabolic Modulation of Anti-Tumor Immunity
Session Chair: Greg M. delgoffe, UPMC Hillman cancer center, pittsburgh, pennsylvania
10:25 a.m.-12:30 p.m.
Metabolic modulation during in vitro expansion for curative adoptive cell therapy for cancer
Greg M. Delgoffe
Obesity and immunometabolism in cancer immunotherapy
Jeffrey C. Rathmell, Vanderbilt University Medical Center, Nashville, Tennessee
Tailoring T cell anti-tumor immunity via reprogramming mitochondria-guided transcription networks
Ping-Chih Ho, University of Lausanne, Lausanne, Switzerland
Dgat1 camouflages sexual dimorphism in anti-tumor CD8+ T cell immunity*
Alaa Madi, German Cancer Research Center, Heidelberg, Germany
Panel Discussion
lunch on own/free time
12:30-2:30 p.m.
plenary session 6: tcr-targeted immunotherapies
Session Chair: Catherine j. Wu, dana-farber cancer institute, boston, massachusetts
2:30-4:35 p.m. | metropolitan ballroom west
T cell specificity, phenotype, and dynamics: Impact on cancer immunotherapy
Catherine J. Wu
Cancer Neoantigens: From Discovery to the Clinic
Nina Bhardwaj, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
Specificity matters: The breadth of endogenous and elicited anti-tumor T cell responses
Paul G. Thomas, St. Jude Children’s Research Hospital, Memphis, Tennessee
Hallmarks of CD8 T cell dysfunction are established within hours of tumor antigen encounter prior to cell division*
Mary Philip, Vanderbilt University Medical Center, Nashville, Tennessee
Panel Discussion
Poster session b/reception
4:45-7 p.m. | metropolitan ballroom east
Posters to be presented at the conference
Evening Off/Dinner on own
7 P.M.
Wednesday, october 4
Continental Breakfast
7-8 a.m. | metropolitan ballroom centre
plenary session 7: spatial profiling
sESSION cHAIR: Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, New York
8-9:50 a.m. | metropolitan ballroom west
Identifying regulators of tumor immunity by spatial functional genomics
Brian D. Brown
Recirculating tumor-specific T cell responses as biomarkers for virally driven cancers
Evan Newell, Fred Hutchinson Cancer Research Center, Seattle, Washington
Communication is key: Understanding the modulating effect of immune cell crosstalk on T cell therapy function
Amber K. L. Wezenaar, Princess Maxima Centrum, Utrecht, Netherlands
Panel Discussion
Break
9:50-10:05 a.m. | metroplitan ballroom foyer
Plenary session 8: synthetic biology and immune cell engineering
Session Chair: Phillip D. Greenberg, Fred Hutchinson Cancer Research Center, SEattle, Washington
10:05-11:55 a.m. | metropolitan ballroom west
Gene deletions unveiled: Cracking the code for CAR T cell supremacy
Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania
‘Ain’t no mountain high enough’: Making TCR-T cells work against solid tumors
Philip D. Greenberg
Title to be announced
Michael Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York
Panel Discussion
Break
11:55 a.m.-12:10 p.m. | metropolitan ballroom foyer
plenary session 9: engineered cytokines
Session Chair: Mario Sznol, Yale University, New Haven, Connecticut
12:10-2 p.m. | metropolitan ballroom west
PD1-IL2v: PD-1-Cis IL-2Rβγ agonism yields better T cell effectors from stem-like CD8+ T cells
Pablo Umana, Roche, Schlieren, Switzerland
Restricting the activity of IL-2 and IL-21 to CD8+ T cells greatly enhances their therapeutic potential
Ivana Djuretic, Asher Biotherapeutics, Inc., South San Francisco, California
Challenges in cancer immunotherapy: Connecting the solutions to the problems
Mario Sznol
closing comments and departure
2 p.m. | metropolitan ballroom west
Mario Sznol, Yale University, New Haven, Connecticut
* Short talk from proffered paper